The biotechnology platform conducts CTC tests on a given blood sample, analyzes gradual cell growth, tracks serum secretion and marks abnormal and rapid multiplication of bio molecules and protein cells and sends signals when a high number of circulating nontumor epithelial cells is released into the blood, enabling medical researchers to detect cancer before biopsy and develop alternative cancer treatment therapies that are non-invasive, painless and cheap. Rarecells® Diagnostics is a science-driven company and has the exclusive license of patents belonging to the French Public Institutions University Paris Descartes, Assistance Publique Hôpitaux de Paris and INSERM protecting the Rarecells® Device and its consumables, as well as the analyses performed on cells isolated using the Rarecells® System.